Assessing Preoperative Nepafenac 0.1% For Post-Surgical Inflammation Control In Cataract Procedures.

Introduction: Cataract surgery, widely performed for significant visual improvement, often encounters postoperative inflammation, potentially leading to complications like cystoid macular edema (CME) and elevated intraocular pressure (IOP). Effective management of inflammation is critical for optimal recovery. This study evaluates the impact of preoperative nepafenac 0.1% on postoperative inflammation in uncomplicated cataract surgeries in healthy subjects. Aims and Objectives: To assess the effectiveness of preoperative topical nepafenac 0.1% in controlling postoperative inflammation. Primary objectives include measuring best-corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP), and aqueous flare values preoperatively and at 15, 30, and 60 days postoperatively. Materials and methods: A prospective, randomized, controlled study with 100 healthy subjects undergoing uncomplicated cataract surgery. Group A (n=50) received preoperative nepafenac 0.1%; Group B (n=50) did not. Standard phacoemulsification was performed by a single surgeon. Postoperative evaluations included BCVA, IOP, CMT, and aqueous flare values. Results: No significant differences were observed between Group A and Group B in terms of age, gender distribution, preoperative BCVA, IOP, or CMT. Postoperatively, Group A showed significantly lower aqueous flare values (p<0.05) on days 1, 15, 30, and 60. BCVA and CMT improvements were not statistically significant, and IOP remained stable across both groups. Conclusion: Preoperative nepafenac 0.1% significantly reduces postoperative aqueous flare, indicating reduced intraocular inflammation. However, its impact on BCVA and CMT was not statistically significant. These findings support nepafenac's role in perioperative inflammation management in cataract surgery. [ABSTRACT FROM AUTHOR]